As EV-packaged molecules have been identified as potential biomarkers and therapeutic targets in various cancers (36), we evaluated the clinical relevance of EV-packaged hnRNPA1 in KRASG12D PDAC at 2 independent clinical centers (96 patients from Sun Yat-Sen Memorial Hospital of Sun Yat-sen University, and 76 patients from Guangdong Provincial People’s Hospital). This evidence concerns the gene HNRNPA1 and cancer.